{"groups":[{"description":"Pembrolizumab: 200 mg IV dose given on day 1 of a three week cycle\n\nRituximab: 375 mg/m2 IV dose given up to 8 times in the trial","id":"FG000","title":"Pembrolizumab and Rituximab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}